Aspergillus allergy refers to an immune overreaction to proteins produced by Aspergillus fungi, most commonly Aspergillus fumigatus, and it ranges from mild sensitization that shows up on a skin test to a destructive lung condition called allergic bronchopulmonary aspergillosis (ABPA). Among people with asthma, sensitization to Aspergillus runs anywhere from about 6% to nearly 40%, and a pooled estimate puts the rate of full-blown ABPA at roughly 8% of asthmatics worldwide. That gap between “allergic on paper” and “seriously ill” is where much of the confusion around this topic lives, and the distinction matters for treatment decisions, long-term lung health, and everyday environmental choices.
What Happens Inside the Airways
Aspergillus spores are everywhere outdoors and in most indoor environments. You inhale them daily. In most people the immune system clears them without fuss. In susceptible individuals, the fungus manages to linger in the airways long enough to provoke a strong allergic cascade. The key problem is a lopsided immune response: instead of the type of inflammation that efficiently kills fungi, the body mounts a type-2 immune response dominated by certain white blood cells and signaling molecules that drive allergic inflammation rather than fungal clearance.
Research shows that when Aspergillus spores begin to swell and germinate inside the airway, they become far more potent at triggering this allergic response. In laboratory models, immune cells exposed to spores that had begun swelling (around three hours after landing) provoked a dramatic influx of eosinophils, neutrophils, and activated T cells into the airways, along with proteins associated with allergic inflammation.
The result is a self-reinforcing cycle: the fungus persists because the immune system chose the wrong battle plan, and the ongoing allergic inflammation damages airway tissue, which makes the environment even friendlier for the fungus. A recent review frames this as a triad of host genetic susceptibility, persistent airway colonization, and an exaggerated type-2 immune profile, all three feeding into each other.
The Spectrum From Sensitization to Serious Disease
Not everyone who tests positive for Aspergillus allergy has the same condition. Clinicians recognize several distinct points along a spectrum, and where you fall determines how aggressively the problem needs to be managed.
- Aspergillus sensitization: Your immune system produces IgE antibodies against Aspergillus proteins, detectable by skin prick test or blood test, but you may have no symptoms beyond your baseline asthma. No specific treatment for the sensitization itself is usually needed.
- Severe asthma with fungal sensitization (SAFS): You have difficult-to-control asthma plus evidence of fungal sensitization but don’t meet the full criteria for ABPA. SAFS carries a greater burden and higher risk of irreversible airway damage compared to asthma alone.
- Allergic bronchopulmonary aspergillosis (ABPA): The full syndrome, defined by a combination of active asthma, elevated blood eosinophils, a very high total IgE level, fleeting shadows on chest imaging, central bronchiectasis, and confirmed Aspergillus sensitization.
SAFS and ABPA are driven by different underlying disease processes despite looking superficially similar, which makes accurate classification important. Genetic studies have found distinct immune-gene associations for SAFS compared to ABPA, reinforcing that these are not simply mild and severe versions of the same condition.
The classic presentation of ABPA includes asthma that doesn’t respond well to standard inhalers, recurrent lung infiltrates that appear and disappear on chest X-rays, and progressive bronchiectasis. In an early landmark series, all patients had markedly elevated serum IgE, and abnormal airway imaging was a universal finding.
When Aspergillus Allergy Affects the Sinuses
The lungs get most of the attention, but Aspergillus allergy can also settle into the sinuses. Allergic fungal rhinosinusitis (AFRS) is a subset of chronic sinusitis with nasal polyps in which the sinuses fill with thick, eosinophil-rich “allergic mucin” containing fungal material. It was first described as a distinct entity in the early 1980s, when researchers identified a characteristic mucinous material packed with eosinophils, Charcot-Leyden crystals, and fungal hyphae in sinus tissue.
AFRS develops in people with healthy immune systems, but geography and climate play a role: warm, humid regions report higher rates. Compared to other forms of Aspergillus sinus disease (like a simple fungal ball), patients with the allergic form are significantly more likely to have underlying allergies, allergic rhinitis, asthma, and nasal polyps, and they show higher blood eosinophil counts and IgE levels. The immune pathways involved look a lot like those in ABPA, with prominent type-2 inflammation, though AFRS research has increasingly recognized innate immune pathways as well.
How the Diagnosis Is Made
Diagnosing Aspergillus allergy, especially ABPA, has never been straightforward. The condition was first described in 1952, yet it took until 1977 for the first formal diagnostic criteria to be published, and clinicians have been refining those criteria ever since. The most recent revision comes from the 2024 ISHAM working group guidelines.
The starting point is usually a skin prick test or a blood test measuring specific IgE antibodies against A. fumigatus. Both have their quirks. In one study of patients with severe asthma, about 45% showed sensitization to A. fumigatus, but overall agreement between skin testing and blood IgE for individual fungi was modest, ranging from about 14% to 56% depending on the species. That means a negative skin test doesn’t always rule out sensitization, and a positive blood test doesn’t always match a positive skin test. Using both methods together catches more cases.
Total serum IgE is another cornerstone. In ABPA it’s typically very high, often many times above the normal range. Blood eosinophil counts add another data point. Imaging findings, discussed below, round out the picture.
Molecular Allergen Testing
Newer laboratory approaches test for IgE against specific Aspergillus proteins (called recombinant allergens) rather than the whole crude fungal extract. This matters because crude extract testing can’t distinguish someone who is truly sensitized to Aspergillus from someone whose immune system is simply cross-reacting with proteins shared by other common molds. Research in Japanese patients found that IgE levels against two specific proteins, Asp f 1 and Asp f 2, effectively separated ABPA from simple Aspergillus-sensitized asthma. Another study found that a specialized lab test measuring immune-cell activation to the protein Asp f 4 was significantly higher in ABPA patients than in those with sensitization alone.
These molecular tests are not yet routine everywhere, but they’re becoming more available and can help resolve ambiguous cases where the standard workup leaves the diagnosis uncertain.
Imaging Clues
CT scans often reveal distinctive findings in ABPA. Central bronchiectasis, meaning dilated airways concentrated in the upper and middle lung lobes, is the hallmark. In one imaging study, 86 patients showed this pattern, with centrilobular nodules in a “tree-in-bud” pattern appearing in 86% of cases and mucus plugs (mucoceles) in 59%. The mucus itself is generally low-density on CT, but in up to about 20% of patients it becomes hyperdense, meaning it appears brighter than surrounding tissue. When the mucus is visibly bright on an unenhanced scan, it’s a strong pointer toward ABPA and essentially rules in the diagnosis for experienced radiologists.
Treatment Options
Managing Aspergillus allergy depends on where you sit on the spectrum. Simple sensitization with well-controlled asthma may not need any Aspergillus-specific treatment at all. ABPA is a different story.
Corticosteroids
Oral corticosteroids remain the first-line treatment for acute ABPA flares. They suppress the overactive immune response, bring down IgE levels, and clear lung infiltrates. However, a randomized trial comparing higher and lower steroid doses found that the outcomes after one and two years were similar between the groups, while the higher-dose group accumulated more than double the total steroid exposure and experienced significantly more side effects, including weight gain and skin changes. The takeaway: moderate-dose regimens can be just as effective with fewer harms.
Antifungal Drugs
Itraconazole, an oral antifungal, works by reducing the fungal burden in the airways so there’s less allergic fuel on the fire. A randomized trial found that about 46% of patients responded to itraconazole versus 19% on placebo. A second randomized trial confirmed fewer exacerbations requiring oral steroids in patients taking itraconazole. It’s not a replacement for steroids in acute flares, but it’s a useful add-on that can reduce how much steroid a patient needs over time.
Biologic Therapies
The real shift in ABPA management over the past decade has been the arrival of biologic drugs that target specific immune pathways. Omalizumab, which blocks IgE, was the first to gain traction. Case reports of children with cystic fibrosis and steroid-dependent ABPA showed sustained clinical improvement after starting omalizumab, allowing them to stop chronic oral steroids entirely. A systematic review and meta-analysis quantified the benefits: omalizumab cut annual exacerbation rates by roughly two per year, improved lung function by about 12%, and allowed a meaningful reduction in daily steroid dose.
Dupilumab and mepolizumab, biologics that target different parts of the type-2 immune cascade, have also shown promise. A broader meta-analysis pooling data on all three biologics found that omalizumab, dupilumab, and mepolizumab each significantly reduced exacerbation rates, steroid doses, and total IgE levels in ABPA patients. Benralizumab, another biologic, was included in the pooled analysis but had less data behind it. These therapies are particularly valuable for patients who can’t tolerate long-term steroids or who keep relapsing when steroids are tapered.
Genetic Susceptibility
Why does one asthmatic with Aspergillus exposure develop ABPA while another doesn’t? Genetics plays a meaningful role. Several gene variants have been linked to ABPA risk, including certain HLA types (the immune-system molecules that present foreign proteins to T cells), variants in the receptor for a key allergic signaling molecule (IL-4), changes in the surfactant protein genes that help coat the lung lining, and mutations in the cystic fibrosis gene CFTR. These variants collectively tilt the immune system toward a stronger type-2 allergic response to Aspergillus antigens.
Researchers have proposed that HLA restriction, specifically the HLA-DR2 and DR5 types, is a necessary but not sufficient condition for developing ABPA. In other words, you need the genetic setup, but you also need enough fungal exposure and possibly other immune or environmental triggers to push you over the edge into disease. This helps explain why ABPA clusters in certain families and why it’s more common in people with cystic fibrosis, who carry CFTR mutations that impair airway clearance and create an ideal fungal habitat.
The Cystic Fibrosis Connection
People with cystic fibrosis deserve special mention because ABPA is both common and easy to miss in this population. The thick, sticky airway mucus characteristic of CF creates ideal conditions for A. fumigatus to colonize and persist. Once the fungus establishes itself, the same IgE-driven hypersensitivity response kicks in, causing additional inflammation, bronchospasm, and worsening bronchiectasis on top of what CF already causes.
The diagnostic challenge is that many ABPA symptoms, including worsening cough, declining lung function, and new shadows on imaging, overlap heavily with a routine CF exacerbation. Clinicians are advised to suspect ABPA when a CF patient deteriorates and the decline can’t be attributed to a bacterial infection or other known cause, especially if total IgE is markedly elevated and Aspergillus sensitization is confirmed. Co-colonization with both Pseudomonas aeruginosa (the most common CF bacterial pathogen) and A. fumigatus occurs in roughly 16% of CF patients, and the combination complicates management because treating one pathogen doesn’t necessarily address the other.
Treatment follows the same general principles as in non-CF patients: steroids to control the immune response, antifungals to reduce fungal load, and increasingly biologics like omalizumab for steroid-dependent cases. The steroid side-effect burden is an especially acute concern in children with CF, who are already dealing with growth impairment, bone-density issues, and diabetes risk from the disease itself.
Cross-Reactivity With Other Molds
If you’re allergic to Aspergillus, there’s a decent chance your immune system also reacts to related fungi. Cross-reactivity among different mold species is well-documented: Aspergillus and Penicillium share about 20% antigenic cross-reactivity, while cross-reactivity between Aspergillus and Stachybotrys (the “black mold” that gets so much media attention) is lower, around 8-9%. That’s less overlap than many people assume, but it’s enough to produce positive tests for molds you’ve never meaningfully been exposed to.
This cross-reactivity is one reason why molecular allergen testing (using specific recombinant proteins rather than crude extracts) is gaining ground. Crude extracts contain dozens of proteins, some of which are shared across mold species, so a positive test to crude Aspergillus extract might actually reflect sensitization to a different mold entirely. Testing for species-specific proteins helps sort out who is truly Aspergillus-allergic from who is cross-reacting.
Indoor Exposure and What You Can Control
Aspergillus is one of the most common fungi found inside homes. A study of urban households identified it among the predominant indoor fungi alongside Cladosporium, Penicillium, and Alternaria. Moisture is the key driver of indoor fungal growth: homes with indicators of dampness, including visible mold and even cockroach presence as a proxy for moisture problems, showed elevated Aspergillus spore levels. A separate study adjusting for age, sex, and family allergy history found that higher indoor Aspergillus spore counts were independently associated with increased allergic sensitization.
For someone with known Aspergillus allergy or ABPA, environmental control becomes a practical priority. Keeping indoor humidity below 50%, fixing leaks promptly, ensuring adequate ventilation in bathrooms and kitchens, and using HEPA-filtered air purifiers can all reduce spore counts. Composting bins, potted plants with damp soil, and old building materials are common but often overlooked indoor sources. Complete avoidance of Aspergillus spores is impossible since they’re ubiquitous outdoors, but reducing the fungal load in your home breathing space can meaningfully cut exposure in the place where you spend most of your time.
How Climate Change Could Shift Aspergillus Geography
Aspergillus distribution isn’t static. Climate modeling suggests that warming temperatures will push suitable habitat for pathogenic Aspergillus species toward the poles over the coming decades. Under moderate warming scenarios, Aspergillus habitat suitability in parts of the Southern Hemisphere, including much of Australia, is projected to decline substantially by 2100, while new suitable zones emerge across northern China, Russia, Scandinavia, and Alaska. Under more severe warming, large portions of Africa and Brazil also lose suitability while higher northern latitudes gain it.
For allergy and respiratory medicine, the practical implication is that populations in northern regions that historically had lower Aspergillus exposure may face rising rates of sensitization and ABPA in coming decades, while some tropical and subtropical areas might see reduced fungal burdens. These projections are model-based and carry uncertainty, but they track with the broader pattern of fungal diseases expanding their geographic range as temperatures climb. Clinicians in newly affected regions may need to add Aspergillus allergy to their diagnostic radar for asthma patients who aren’t responding to standard treatment.